Skip to content

ALDEYRA THERAPEUTICS, INC.: 10-Q filed 2014-06-11

What ALDEYRA THERAPEUTICS, INC. reported in its quarterly report filed 2014-06-11 (fiscal Q1 2014): 27 published measures, 80 facts as tagged in accession 0001193125-14-233411.

This filing

Form
10-Q (quarterly report)
Filed
2014-06-11
Fiscal period
fiscal Q1 2014
Accession
0001193125-14-233411 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ALDEYRA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-312,890,566USD
At 2013-12-313,743,233USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-314,027,135USD
At 2013-12-315,647,261USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-31-39,645,435USD
At 2013-12-31-40,221,326USD
At 2012-12-31-54,384,496USD
At 2011-12-31-15,512,997USD
At 2010-12-31-12,969,489USD
At 2009-12-31-9,210,595USD
At 2008-12-31-4,057,955USD
At 2007-12-31-1,847,171USD
At 2006-12-31-1,324,189USD
At 2005-12-31-385,213USD
At 2004-12-31947USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-03-312,145,621USD
At 2013-12-313,262,354USD
At 2013-03-311,676,053USD
At 2012-12-311,223,638USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31401,773USD90
2004-08-13 to 2014-03-31-24,630,940USD3518
2013-01-01 to 2013-12-3113,060,472USD365
2013-01-01 to 2013-03-31-3,974,933USD90
2012-01-01 to 2012-12-31-23,074,515USD366
2011-01-01 to 2011-12-31-2,378,064USD365
2010-01-01 to 2010-12-31-3,590,169USD365
2009-01-01 to 2009-12-31-4,975,228USD365
2008-01-01 to 2008-12-31-2,224,375USD366
2007-01-01 to 2007-12-31-523,032USD365
2006-01-01 to 2006-12-31-939,026USD365
2005-01-01 to 2005-12-31-386,454USD365
2004-08-13 to 2004-12-31-2,322USD141

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2004-08-13 to 2014-03-317,942USD3518

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-01-01 to 2014-03-31327,365shares90
2013-01-01 to 2013-03-31314,419shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-01-01 to 2014-03-31443,826shares90
2013-01-01 to 2013-03-31314,419shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-0.04USD/shares90
2013-01-01 to 2013-03-31-13.03USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-4USD/shares90
2013-01-01 to 2013-03-31-13.03USD/shares90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-03-31365,686USD90
2004-08-13 to 2014-03-312,371,865USD3518
2013-01-01 to 2013-03-3150,447USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-1,244,924USD90
2004-08-13 to 2014-03-31-20,451,923USD3518
2013-01-01 to 2013-03-31-291,538USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-03-312,155,362USD
At 2013-12-313,270,766USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-01 to 2014-03-31113,221USD90
2004-08-13 to 2014-03-311,102,372USD3518
2013-01-01 to 2013-03-3115,403USD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-31691,501USD
At 2013-12-31605,011USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-03-31165,961USD
At 2013-12-31341,853USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-03-31444,278USD90
2004-08-13 to 2014-03-3113,291,427USD3518
2013-01-01 to 2013-03-31150,233USD90

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-03-311,276,803USD
At 2013-12-311,102,685USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-03-31133,071USD
At 2013-12-31117,873USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-03-319,741USD
At 2013-12-318,412USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-13,237USD90
2004-08-13 to 2014-03-31-53,772,497USD3518
2013-01-01 to 2013-03-31-4,098,092USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31800,646USD90
2004-08-13 to 2014-03-317,160,496USD3518
2013-01-01 to 2013-03-31141,305USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2004-08-13 to 2014-03-317,942USD3518

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-01-01 to 2014-03-311,646,697USD90
2004-08-13 to 2014-03-31-4,179,017USD3518
2013-01-01 to 2013-03-31-3,683,395USD90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2004-08-13 to 2014-03-313,773USD3518

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-175,892USD90
2004-08-13 to 2014-03-31165,961USD3518
2013-01-01 to 2013-03-31-61,915USD90

Inspect the source

Entity
ALDEYRA THERAPEUTICS, INC. / CIK 0001341235
Captured
2026-09-20T07:54:15.451Z
SEC response SHA-256
71cda24b59474759e40949f545ab949ecdfc2871814e3cf45050931d1c516763

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001341235.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))